Keros Therapeutics (KROS) EBIT Margin (2019 - 2025)
Keros Therapeutics' (KROS) quarterly EBIT Margin came in at 15569.15% in Q4 2025, down 1381852.0% YoY from N/an in Q4 2024, and down 14193.98% on a QoQ basis from 108.92% in Q3 2025.
Keros Therapeutics (KROS) EBIT Margin (2019 - 2025) Analysis & Trends
Keros Therapeutics (KROS) has 6 years of EBIT Margin data on file, last reported at 15569.15% in Q4 2025.
- Quarterly EBIT Margin fell 1381852.0% year-over-year to 15569.15% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 27.72% (up 602923.0% YoY) and the FY2025 annual result came in at 27.71%, up 596667.0% from the prior year.
- EBIT Margin eased to 15569.15% in Q4 2025, from 108.92% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 71.97% in Q1 2025 to a low of 541000.0% in Q3 2023.
- A 5-year average of 56691.26% and a median of 8434.2% in 2024 frame the typical range for EBIT Margin.
- Annual changes were most pronounced in 2024 — EBIT Margin jumped 52588222 bps — and 2025, when it plunged 1381852 bps.
- Tracing KROS's EBIT Margin over 5 years: stood at 27.18% in 2021, then plunged by 393 bps to 134.03% in 2022, then plunged by 24137 bps to 32486.01% in 2023, then soared by 95 bps to 1750.62% in 2024, then sank by 789 bps to 15569.15% in 2025.
- The last three EBIT Margin figures came in at 15569.15% (Q4 2025), 108.92% (Q3 2025), and 219.16% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 17.93% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -35.57% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.36% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.75% |
| 10 | Keros Therapeutics | 217.61 Mn | -40.00 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -15,569.15% |
| Sep 30, 2025 | -108.92% |
| Jun 30, 2025 | -219.16% |
| Mar 31, 2025 | 71.97% |
| Dec 31, 2024 | -1,750.62% |
| Sep 30, 2024 | -15,117.78% |
| Mar 31, 2024 | -58,413.25% |
| Dec 31, 2023 | -32,486.01% |
| Sep 30, 2023 | -541,000.00% |
| Mar 31, 2022 | -134.03% |
| Dec 31, 2021 | -27.18% |
| Jun 30, 2021 | -15,541.00% |
| Dec 31, 2019 | -109.12% |
| Sep 30, 2019 | -93.04% |
| Jun 30, 2019 | -106.04% |
| Mar 31, 2019 | -114.32% |